Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19996824 | 0.86 | KMT2A (0.39) | MEN1KMT2AGRIA1RENCA1 | |
| SCHEMBL17771177 | 0.85 | REN (0.40) | MEN1KMT2AGRIA1RENCA1 | |
| SCHEMBL10147425 | 0.84 | GRIA1 (0.50) | MEN1KMT2AGRIA1RENCA1 | |
| SCHEMBL3433536 | 0.79 | GRIA1 (0.43) | MEN1KMT2AGRIA1RENCA1 | |
| SCHEMBL23542459 | 0.77 | GRIA1 (0.71) | GRIA1RENCA1CA2CA12 | |
| SCHEMBL14004444 | 0.77 | CA1 (0.58) | GRIA1CA1CA2CA12CA7 | |
| SCHEMBL1727287 | 0.77 | GRIA1 (0.46) | MEN1KMT2AGRIA1RENCA1 | |
| SCHEMBL17771179 | 0.77 | GRIA1 (0.47) | GRIA1RENCA1CA2CA12 | |
| SCHEMBL26724826 | 0.77 | CA1 (0.50) | GRIA1RENCA1CA2CA12 | |
| SCHEMBL12232575 | 0.77 | GRIA1 (0.57) | MEN1KMT2AGRIA1RENCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2023-01-05 | — | — | US | disclosed |
| US-9926321-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926321-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160264577-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-09-15 | — | — | US | disclosed |
| US-9346808-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-24 | — | — | US | disclosed |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PEBP1, PLTP | MEN1 3355/4885KMT2A 4194/4885GRIA1 3399/4885 |
| US-20160264577-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | MEN1 2755/4885KMT2A 3715/4885GRIA1 2975/4885 |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | MEN1 3396/4885KMT2A 4165/4885GRIA1 2780/4885 |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, NSUN2 | MEN1 4836/4885KMT2A 1664/4885GRIA1 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.